| Monday, August 17, 2009 | ||
| 07:30:00 | Registration and Morning Coffee | |
| 08:20:00 | Chairperson’s Opening Remarks | William M. Egan |
| 08:30:00 | Plenary Keynote Presentation Vaccines: Challenges for the Future | Norman W Baylor |
| 09:15:00 | Plenary Featured Presentation Risk-Based Modelling for Vaccine Supply Chain Capacity Assessment | Susan Behrens |
| 10:00:00 | Networking Coffee Break with Exhibit and Poster Viewing | |
| 10:05:00 | INFLUENZA | |
| 11:00:00 | Chairperson’s Remarks | William M. Egan |
| 11:05:00 | Vaccine Industry’s Contribution to Global Pandemic Preparedness | Norbert W. Hehme |
| 11:35:00 | Vaccines and Immunotherapeutics Against Influenza: Technologies, Needs, Demands, and Future | Suryaprakash Sambhara |
| 12:05:00 | PATH’s Influenza Vaccine Program: Vaccine Development for People in Developing Countries | Rick Bright |
| 12:35:00 | Lunch on Your Own (Lunch Presentation Opportunity Available) | |
| 13:50:00 | CANCER | |
| 13:55:00 | Chairperson’s Remarks | Eid Haddad |
| 14:00:00 | Passive Vaccination Using Redirected, Genetically Engineered, Designer T-Cells for Immunotherapy | Zelig Eshhar |
| 14:30:00 | Live Bacterial Vaccines: The Use of Bioengineered Listeria Monocytogenes in the Clinic | John Rothman |
| 15:00:00 | Sponsored Presentation (Opportunity Available) | |
| 15:15:00 | Networking Refreshment Break with Exhibit and Poster Viewing | |
| 15:55:00 | HIV/AIDS | |
| 16:00:00 | Structure-Based Rational Design of HIV Env Immunogens for Vaccine Development | Indresh K. Srivastava |
| 16:30:00 | The HIV-1 gp120 C5 Region as a Candidate Therapeutic Vaccine to Prevent Disease Progression | Angus Dalgleish |
| 17:00:00 | Strategies for Effective Gene-Based Vaccines: Results from Clinical and Pre-Clinical Studies | Margaret A. Liu |
| Tuesday, August 18, 2009 | ||
| 07:20:00 | Check-In | |
| 07:30:00 | Morning Coffee (Breakfast Sponsored Presentation Opportunity Available) | |
| 07:35:00 | VACCINE PLATFORM INNOVATIONS | |
| 08:25:00 | Chairperson’s Remarks | |
| 08:30:00 | Development of a Novel Baculovirus-Insect Cell System to Assess the Impact of Protein Glycosylation on Influenza Virus Subunit Vaccines | Donald Jarvis |
| 09:00:00 | Chimigen Platform Technology: A Platform of the Future for Immunotherapeutic Vaccine Development | Rajan George |
| 09:30:00 | ApoVax104 as a Novel Therapeutic Vaccine | Haval Shirwan |
| 10:00:00 | Networking Coffee Break with Exhibit and Poster Viewing | |
| 10:00:00 | VACCINE DEVELOPMENT PATHWAY— STEPS ALONG THE WAY | |
| 10:45:00 | Vaccines: WIIFM (or I): An Industry Perspective on Vaccine Investment Decision Making | Frank Malinoski |
| 11:15:00 | Interactive Panel Discussion How to Fund Vaccine Research & Development in Today’s Economy | |
| 12:15:00 | End of “Novel Vaccines: Design & Development” meeting | |
| 12:30:00 | End Of Day Two | |
How We Rank